社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
llipinggg
IP属地：未知
+关注
帖子 · 250
帖子 · 250
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
llipinggg
llipinggg
·
2021-12-29
Like
10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>
Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. Mc
10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>
看
1,942
回复
评论
点赞
4
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-28
Like
非常抱歉，此主贴已删除
看
2,775
回复
2
点赞
5
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-27
Like
Novavax shares dropped 8% in morning trading<blockquote>Novavax股价早盘下跌8%</blockquote>
Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.
Novavax shares dropped 8% in morning trading<blockquote>Novavax股价早盘下跌8%</blockquote>
看
2,047
回复
1
点赞
9
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-26
Like
Clover Health Is Not the $2 Billion Stock to Buy for 2022<blockquote>Clover Health不是2022年值得购买的20亿美元股票</blockquote>
Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth
Clover Health Is Not the $2 Billion Stock to Buy for 2022<blockquote>Clover Health不是2022年值得购买的20亿美元股票</blockquote>
看
2,522
回复
评论
点赞
4
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-25
Like
非常抱歉，此主贴已删除
看
1,992
回复
评论
点赞
7
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-24
Like
非常抱歉，此主贴已删除
看
2,996
回复
2
点赞
12
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-23
Like
U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>
U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea
U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>
看
2,468
回复
评论
点赞
8
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-22
Like
Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>
Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco
Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>
看
3,496
回复
1
点赞
5
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-21
Like
非常抱歉，此主贴已删除
看
2,283
回复
评论
点赞
3
编组 21备份 2
分享
举报
llipinggg
llipinggg
·
2021-12-20
Lime
Dow falls 500 points to start the week as omicron continues to spook markets<blockquote>由于奥密克戎继续令市场恐慌，道琼斯指数本周初下跌500点</blockquote>
Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considerin
Dow falls 500 points to start the week as omicron continues to spook markets<blockquote>由于奥密克戎继续令市场恐慌，道琼斯指数本周初下跌500点</blockquote>
看
2,695
回复
1
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576377533433583","uuid":"3576377533433583","gmtCreate":1613285558478,"gmtModify":1613285558478,"name":"llipinggg","pinyin":"llipinggg","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":20,"headSize":207,"tweetSize":250,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692016294,"gmtCreate":1640790929927,"gmtModify":1640790930233,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692016294","repostId":"1147073840","repostType":4,"repost":{"id":"1147073840","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640786111,"share":"https://www.laohu8.com/m/news/1147073840?lang=zh_CN&edition=full","pubTime":"2021-12-29 21:55","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147073840","media":"Benzinga","summary":"Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. Mc","content":"<p><html><head></head><body>Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. McDonald's shares fell 0.1% to close at $267.88 on Tuesday.</p><p><blockquote><html><head></head><body>Tigress Financial将麦当劳公司（纽约证券交易所股票代码：MCD）的目标股价从271美元上调至314美元。麦当劳股价周二下跌0.1%，收于267.88美元。</body></html></blockquote></p><p>Argus Research boosted the price target on Cintas Corporation (NASDAQ:CTAS) from $410 to $490. Cintas shares rose 0.5% to close at $444.10 on Tuesday.</p><p><blockquote>Argus Research将Cintas Corporation（纳斯达克股票代码：CTAS）的目标价从410美元上调至490美元。Cintas股价周二上涨0.5%，收于444.10美元。</blockquote></p><p>Needham boosted Tenable Holdings, Inc. (NASDAQ:TENB) price target from $62 to $66. Tenable shares fell 0.8% to close at $55.46 on Tuesday.</p><p><blockquote>Needham将Tenable Holdings，Inc.（纳斯达克：TENB）的目标价从62美元上调至66美元。Tenable股价周二下跌0.8%，收于55.46美元。</blockquote></p><p>B of A Securities cut Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price target from $37 to $34. Kiniksa Pharmaceuticals shares rose 1.8% to $12.35 in pre-market trading.</p><p><blockquote>B of A Securities将Kiniksa Pharmaceuticals，Ltd.（纳斯达克股票代码：KNSA）的目标价从37美元下调至34美元。Kiniksa Pharmaceuticals股价在盘前交易中上涨1.8%至12.35美元。</blockquote></p><p>HC Wainwright & Co. raised Dynavax Technologies Corporation (NASDAQ:DVAX) price target from $23 to $28. Dynavax Technologies shares gained 1.4% to $14.40 in pre-market trading.</p><p><blockquote>HC Wainwright&Co.将Dynavax Technologies Corporation（纳斯达克股票代码：DVAX）的目标价从23美元上调至28美元。Dynavax Technologies股价在盘前交易中上涨1.4%，至14.40美元。</blockquote></p><p>Needham cut the price target on Cellebrite DI Ltd. (NASDAQ:CLBT) from $12 to $9.5. Cellebrite DI shares rose 5.2% to close at $8.35 on Tuesday.</p><p><blockquote>Needham将Cellebrite DI Ltd.（纳斯达克股票代码：CLBT）的目标股价从12美元下调至9.5美元。Cellebrite DI股价周二上涨5.2%，收于8.35美元。</blockquote></p><p>Compass Point boosted Bluerock Residential Growth REIT, Inc. (NYSE:BRG) price target from $14.5 to $27. Bluerock Residential Growth shares fell 1.7% to $26.22 in pre-market trading.</p><p><blockquote>Compass Point将Bluerock Residential Growth REIT，Inc.（纽约证券交易所代码：BRG）的目标价从14.5美元上调至27美元。Bluerock Residential Growth股价在盘前交易中下跌1.7%，至26.22美元。</blockquote></p><p>Needham lowered the price target for <a href=\"https://laohu8.com/S/NABL\">N-able, Inc.</a> (NASDAQ:NABL) from $17 to $13.5. N-able shares fell 2.9% to $10.89 in pre-market trading.</p><p><blockquote>Needham降低了目标价<a href=\"https://laohu8.com/S/NABL\">N-able公司。</a>（纳斯达克：NABL）从17美元涨到13.5美元。N-able股价在盘前交易中下跌2.9%，至10.89美元。</blockquote></p><p>Argus Research raised the price target for Edison International (NYSE:EIX) from $68 to $73. Edison International shares rose 0.1% to $68.21 in pre-market trading.</p><p><blockquote>Argus Research将爱迪生国际公司（纽约证券交易所股票代码：EIX）的目标股价从68美元上调至73美元。爱迪生国际股价在盘前交易中上涨0.1%，至68.21美元。</blockquote></p><p>Needham lifted <a href=\"https://laohu8.com/S/MSP\">Datto Holding Corp.</a> (NYSE:MSP) price target from $29 to $32. Datto Holding shares fell 3.5% to $26.00 in pre-market trading.</p><p><blockquote>李约瑟举起<a href=\"https://laohu8.com/S/MSP\">达托控股公司。</a>（纽约证券交易所股票代码：MSP）目标价为29美元至32美元。Datto Holding股价在盘前交易中下跌3.5%，至26.00美元。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-29 21:55</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. McDonald's shares fell 0.1% to close at $267.88 on Tuesday.</p><p><blockquote><html><head></head><body>Tigress Financial将麦当劳公司（纽约证券交易所股票代码：MCD）的目标股价从271美元上调至314美元。麦当劳股价周二下跌0.1%，收于267.88美元。</body></html></blockquote></p><p>Argus Research boosted the price target on Cintas Corporation (NASDAQ:CTAS) from $410 to $490. Cintas shares rose 0.5% to close at $444.10 on Tuesday.</p><p><blockquote>Argus Research将Cintas Corporation（纳斯达克股票代码：CTAS）的目标价从410美元上调至490美元。Cintas股价周二上涨0.5%，收于444.10美元。</blockquote></p><p>Needham boosted Tenable Holdings, Inc. (NASDAQ:TENB) price target from $62 to $66. Tenable shares fell 0.8% to close at $55.46 on Tuesday.</p><p><blockquote>Needham将Tenable Holdings，Inc.（纳斯达克：TENB）的目标价从62美元上调至66美元。Tenable股价周二下跌0.8%，收于55.46美元。</blockquote></p><p>B of A Securities cut Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price target from $37 to $34. Kiniksa Pharmaceuticals shares rose 1.8% to $12.35 in pre-market trading.</p><p><blockquote>B of A Securities将Kiniksa Pharmaceuticals，Ltd.（纳斯达克股票代码：KNSA）的目标价从37美元下调至34美元。Kiniksa Pharmaceuticals股价在盘前交易中上涨1.8%至12.35美元。</blockquote></p><p>HC Wainwright & Co. raised Dynavax Technologies Corporation (NASDAQ:DVAX) price target from $23 to $28. Dynavax Technologies shares gained 1.4% to $14.40 in pre-market trading.</p><p><blockquote>HC Wainwright&Co.将Dynavax Technologies Corporation（纳斯达克股票代码：DVAX）的目标价从23美元上调至28美元。Dynavax Technologies股价在盘前交易中上涨1.4%，至14.40美元。</blockquote></p><p>Needham cut the price target on Cellebrite DI Ltd. (NASDAQ:CLBT) from $12 to $9.5. Cellebrite DI shares rose 5.2% to close at $8.35 on Tuesday.</p><p><blockquote>Needham将Cellebrite DI Ltd.（纳斯达克股票代码：CLBT）的目标股价从12美元下调至9.5美元。Cellebrite DI股价周二上涨5.2%，收于8.35美元。</blockquote></p><p>Compass Point boosted Bluerock Residential Growth REIT, Inc. (NYSE:BRG) price target from $14.5 to $27. Bluerock Residential Growth shares fell 1.7% to $26.22 in pre-market trading.</p><p><blockquote>Compass Point将Bluerock Residential Growth REIT，Inc.（纽约证券交易所代码：BRG）的目标价从14.5美元上调至27美元。Bluerock Residential Growth股价在盘前交易中下跌1.7%，至26.22美元。</blockquote></p><p>Needham lowered the price target for <a href=\"https://laohu8.com/S/NABL\">N-able, Inc.</a> (NASDAQ:NABL) from $17 to $13.5. N-able shares fell 2.9% to $10.89 in pre-market trading.</p><p><blockquote>Needham降低了目标价<a href=\"https://laohu8.com/S/NABL\">N-able公司。</a>（纳斯达克：NABL）从17美元涨到13.5美元。N-able股价在盘前交易中下跌2.9%，至10.89美元。</blockquote></p><p>Argus Research raised the price target for Edison International (NYSE:EIX) from $68 to $73. Edison International shares rose 0.1% to $68.21 in pre-market trading.</p><p><blockquote>Argus Research将爱迪生国际公司（纽约证券交易所股票代码：EIX）的目标股价从68美元上调至73美元。爱迪生国际股价在盘前交易中上涨0.1%，至68.21美元。</blockquote></p><p>Needham lifted <a href=\"https://laohu8.com/S/MSP\">Datto Holding Corp.</a> (NYSE:MSP) price target from $29 to $32. Datto Holding shares fell 3.5% to $26.00 in pre-market trading.</p><p><blockquote>李约瑟举起<a href=\"https://laohu8.com/S/MSP\">达托控股公司。</a>（纽约证券交易所股票代码：MSP）目标价为29美元至32美元。Datto Holding股价在盘前交易中下跌3.5%，至26.00美元。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLBT":"Cellebrite","DVAX":"德纳维制药","CTAS":"信达思","TGT":"塔吉特","TENB":"Tenable Holdings Inc.","BRG":"Bluerock Residential Growth REIT Inc","BK4532":"文艺复兴科技持仓","BK4504":"桥水持仓","EIX":"爱迪生国际","BK4533":"AQR资本管理(全球第二大对冲基金)","MSP":"Datto Holding Corp.","NABL":"N-able, Inc.","MCD":"麦当劳","KNSA":"Kiniksa Pharmaceuticals Ltd.","BK4114":"综合货品商店"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147073840","content_text":"Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. McDonald's shares fell 0.1% to close at $267.88 on Tuesday.Argus Research boosted the price target on Cintas Corporation (NASDAQ:CTAS) from $410 to $490. Cintas shares rose 0.5% to close at $444.10 on Tuesday.Needham boosted Tenable Holdings, Inc. (NASDAQ:TENB) price target from $62 to $66. Tenable shares fell 0.8% to close at $55.46 on Tuesday.B of A Securities cut Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price target from $37 to $34. Kiniksa Pharmaceuticals shares rose 1.8% to $12.35 in pre-market trading.HC Wainwright & Co. raised Dynavax Technologies Corporation (NASDAQ:DVAX) price target from $23 to $28. Dynavax Technologies shares gained 1.4% to $14.40 in pre-market trading.Needham cut the price target on Cellebrite DI Ltd. (NASDAQ:CLBT) from $12 to $9.5. Cellebrite DI shares rose 5.2% to close at $8.35 on Tuesday.Compass Point boosted Bluerock Residential Growth REIT, Inc. (NYSE:BRG) price target from $14.5 to $27. Bluerock Residential Growth shares fell 1.7% to $26.22 in pre-market trading.Needham lowered the price target for N-able, Inc. (NASDAQ:NABL) from $17 to $13.5. N-able shares fell 2.9% to $10.89 in pre-market trading.Argus Research raised the price target for Edison International (NYSE:EIX) from $68 to $73. Edison International shares rose 0.1% to $68.21 in pre-market trading.Needham lifted Datto Holding Corp. (NYSE:MSP) price target from $29 to $32. Datto Holding shares fell 3.5% to $26.00 in pre-market trading.","news_type":1,"symbols_score_info":{"KNSA":0.9,"TENB":0.9,"CLBT":0.9,"MSP":0.9,"NABL":0.9,"TGT":0.9,"BRG":0.9,"EIX":0.9,"MCD":0.9,"DVAX":0.9,"CTAS":0.9}},"isVote":1,"tweetType":1,"viewCount":1942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696265797,"gmtCreate":1640705548538,"gmtModify":1640705548821,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696265797","repostId":"1118096605","repostType":4,"isVote":1,"tweetType":1,"viewCount":2775,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696382108,"gmtCreate":1640618475036,"gmtModify":1640618475276,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696382108","repostId":"1103486686","repostType":4,"repost":{"id":"1103486686","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640616531,"share":"https://www.laohu8.com/m/news/1103486686?lang=zh_CN&edition=full","pubTime":"2021-12-27 22:48","market":"us","language":"en","title":"Novavax shares dropped 8% in morning trading<blockquote>Novavax股价早盘下跌8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103486686","media":"Tiger Newspress","summary":"Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.","content":"<p>Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.</p><p><blockquote>Novavax股价早盘下跌8%。该股前一交易日下跌3.3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6627c5ec391aa02c9ec15dfc36c8f87\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares dropped 8% in morning trading<blockquote>Novavax股价早盘下跌8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares dropped 8% in morning trading<blockquote>Novavax股价早盘下跌8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-27 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.</p><p><blockquote>Novavax股价早盘下跌8%。该股前一交易日下跌3.3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6627c5ec391aa02c9ec15dfc36c8f87\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103486686","content_text":"Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2047,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698733350,"gmtCreate":1640531626103,"gmtModify":1640531626339,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698733350","repostId":"1166698166","repostType":4,"repost":{"id":"1166698166","kind":"news","pubTimestamp":1640484465,"share":"https://www.laohu8.com/m/news/1166698166?lang=zh_CN&edition=full","pubTime":"2021-12-26 10:07","market":"us","language":"en","title":"Clover Health Is Not the $2 Billion Stock to Buy for 2022<blockquote>Clover Health不是2022年值得购买的20亿美元股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1166698166","media":"InvestorPlace","summary":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth ","content":"<p><div> Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the ...</p><p><blockquote><div>Clover Health（纳斯达克股票代码：CLOV）于1月初完成首日交易，CLOV股票价值约70亿美元。它刚刚完成了与社会资本Hedosophia III的合并...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Is Not the $2 Billion Stock to Buy for 2022<blockquote>Clover Health不是2022年值得购买的20亿美元股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Is Not the $2 Billion Stock to Buy for 2022<blockquote>Clover Health不是2022年值得购买的20亿美元股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-26 10:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the ...</p><p><blockquote><div>Clover Health（纳斯达克股票代码：CLOV）于1月初完成首日交易，CLOV股票价值约70亿美元。它刚刚完成了与社会资本Hedosophia III的合并...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166698166","content_text":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the special purpose acquisition company (SPAC) sponsored by “Silicon Valley venture capitalist” Chamath Palihapitiya.\nToday, as I write this, it’s worth approximately $1.94 billion, 74% less than it’s $7 billion valuation.\nWhen I last wrote about Clover Health in early December,I suggested,“only the most speculative investors ought to be anywhere near this healthcare stock.” Since then, CLOV stock has lost another 9% as we approach the end of the year.\nWhile CLOV stock is trading for pennies over $4, here are three similarly-valued stocks to buy for 2022.\nForget CLOV Stock — Buy This Instead\nAccording toFinviz.com,there are64 stocks with a market capitalization between $1.9 billion and $2 billion. My three picks grow sales, generate profits, and possess solid balance sheets. If you’re lucky, at least one will pay a decent dividend.\nUltimately, all three are, in my opinion, safer bets than CLOV in 2022.\nSonic Automotive(NYSE:SAH) is my first pick. It has a current market cap of $2 billion. Its stock is up 25.77% year-to-date (YTD), 258 basis points less than theS&P 500.\nSonic is one of the top automotive retailers in America. Its 119 dealerships are located in 17 states and represent more than 25 brands. In its latest fiscal year, it sold 93,000 new vehicles and 159,000 used vehicles, generating $9.8 billion in revenue. It expects to grow its revenue to $25 billion by 2025.\nFrom a brand breakdown, luxury accounts for 55% of its sales with BMW, Mercedes, and Audi accounting for 71% of its luxury vehicle sales.\nIn 2021’s third-quarter, its revenues grew by 20.6% to $3.07 billion. Its net income rose 46.9% to $84.7 million and its total debt is$1.97 billion or 56% of its total assets.\nThe company’s Echo Park used car business should be a big contributor as it pushes to $25 billion in sales by 2025.\nThe Second Alternative to CLOV Stock\nSally Beauty Holdings(NYSE:SBH) business and the stock bounced back in 2021. That’s great news for long-time shareholders. Up 42.8% YTD, SBH’s five-year return looks a little better as a result. However, it’s down 29% on a cumulative basis over the past 60 months.\nBack in May 2017, I compared Sally Beauty and Ulta Beauty Holdings(NASDAQ:ULTA). ULTA was on a bit of a roll, while SBH was stumbling and bumbling. So, wisely, I said ULTA was the better stock to buy. Ulta is up 28.2% since — it’s also had its ups and downs — while SBH is up 3.8% over the same period.\nHowever, I thought Sally Beauty’s restructuring at the time was gaining traction. While Covid-19 didn’t help its business, its most recent results are encouraging.\nFor all of fiscal 2021, its sales increased10.3% to $3.87 billion with 10.2% same-store sales growth. Its operating earnings grew 44.2% in 2021 to $622.7 million, and it managed to reduce its debt by $420 million in the past year. That puts its long-term debt at $1.38 billion or 48% of its total assets.\nOn Oct. 1, board member Denise Paulonistook over as chief executive officer (CEO)of the company. She is tasked with growing sales and profits after previous CEO Chris Brinkman thoroughly modernized its beauty business during his six-year tenure.\nA Final Possibility\nMy final alternative is Goldman Sachs BDC(NYSE:GSBD). It was founded in 2012 to make debt and equity investments in middle-market companies — defined as earnings before interest, taxes, depreciation and amortization (EBITDA) earnings of$5 million to $200 million— and merged with Goldman Sachs Middle Market Lending Corp. (MMLC) in October 2020.\nAs a result of the merger, GSBD’s asset base more than doubled to$3.5 billion. The MMLC shareholders received 1.1336 GSBD shares for every share of MMLC.\nGSBD had $3.11 billion in investments and $401.8 million in unfunded commitments for111 portfolio companies across 37 industries at the end of September. Approximately 84% of its assets are first lien loans with an average yield of 8.4%.\nIt’s essential to remember that this is an investment focused on income rather than capital appreciation. The BDC’s current quarterly distribution of $0.50 yields a very high 10.4%.\nDo not buy GSBD if you’re expecting capital appreciation. However, if you’re willing to take on more risk than a guaranteed investment, it’s an excellent way to boost your income portfolio.\nNone of these three alternatives to CLOV stock are a sure thing. But, that said, I don’t believe they possess the same amount of risk as Clover Health.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":2522,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698513920,"gmtCreate":1640445196090,"gmtModify":1640445196363,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698513920","repostId":"2193917872","repostType":4,"isVote":1,"tweetType":1,"viewCount":1992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698850170,"gmtCreate":1640346574159,"gmtModify":1640346574440,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698850170","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":2996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698937949,"gmtCreate":1640273647428,"gmtModify":1640273647655,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698937949","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","kind":"news","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=zh_CN&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对COVID-19的药物，提供了另一种易于使用的药物来对抗不断上升的奥密克戎感染浪潮。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>美国食品和药物管理局批准默克公司的molnupiravir的一天前，该机构批准了辉瑞公司的一种竞争药物。这种名为Paxlovid的药物很可能成为针对该病毒的首选治疗方法，因为它具有优越的益处和较温和的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药物预计对疫情的作用将比几周前预测的要小。它阻止严重新冠肺炎的能力比最初宣布的要小得多，药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于患有COVID-19早期症状且住院风险最高的成年人，包括老年人以及患有肥胖症和心脏病等疾病的人。英国于11月初首次批准了该药物。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有禁止在怀孕期间使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后几天内采取避孕措施，而男性应在最后一次给药后至少三个月内采取避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA顾问小组上个月仅以微弱优势批准了该药物，并警告称其使用必须严格针对能够受益最大的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞药丸的作用方式不同，也没有同样的风险。此外，辉瑞的药物在测试中的有效性大约是三倍，将高危患者的住院和死亡人数减少了近90%，而默克的药物减少了30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克公司的药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>梅奥诊所的格雷戈里·波兰博士在谈到默克公司的药物时说：“如果辉瑞公司的药物供应充足，我认为它不会被使用。”“没有理由，因为它的功效较低且副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA的决定为对抗已导致超过80万美国人死亡的病毒提供了另一种潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录病例、住院和死亡做好准备。包括默克公司在内的抗病毒药物预计对奥密克戎病毒有效，因为它们不针对该变种大多数令人担忧的突变所在的刺突蛋白。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA的决定是基于结果显示，近7%服用该药物的患者最终住院，其中一人在30天后死亡。相比之下，服用安慰剂的住院患者比例为10%，死亡人数为9人。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已同意购买足够治疗310万人的药物。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约700美元，该疗程要求患者每天两次服用四粒药丸，持续五天。哈佛大学和伦敦国王学院的一项审查估计，每个40粒药丸的疗程费用约为18美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖。这种遗传效应引发了人们的担忧，即该药物可能会导致人类胎儿发生突变，甚至刺激更强的病毒株。但FDA科学家表示，变异风险很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">SeattleTimes</strong><span class=\"h-time small\">2021-12-23 22:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对COVID-19的药物，提供了另一种易于使用的药物来对抗不断上升的奥密克戎感染浪潮。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>美国食品和药物管理局批准默克公司的molnupiravir的一天前，该机构批准了辉瑞公司的一种竞争药物。这种名为Paxlovid的药物很可能成为针对该病毒的首选治疗方法，因为它具有优越的益处和较温和的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药物预计对疫情的作用将比几周前预测的要小。它阻止严重新冠肺炎的能力比最初宣布的要小得多，药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于患有COVID-19早期症状且住院风险最高的成年人，包括老年人以及患有肥胖症和心脏病等疾病的人。英国于11月初首次批准了该药物。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有禁止在怀孕期间使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后几天内采取避孕措施，而男性应在最后一次给药后至少三个月内采取避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA顾问小组上个月仅以微弱优势批准了该药物，并警告称其使用必须严格针对能够受益最大的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞药丸的作用方式不同，也没有同样的风险。此外，辉瑞的药物在测试中的有效性大约是三倍，将高危患者的住院和死亡人数减少了近90%，而默克的药物减少了30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克公司的药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>梅奥诊所的格雷戈里·波兰博士在谈到默克公司的药物时说：“如果辉瑞公司的药物供应充足，我认为它不会被使用。”“没有理由，因为它的功效较低且副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA的决定为对抗已导致超过80万美国人死亡的病毒提供了另一种潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录病例、住院和死亡做好准备。包括默克公司在内的抗病毒药物预计对奥密克戎病毒有效，因为它们不针对该变种大多数令人担忧的突变所在的刺突蛋白。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA的决定是基于结果显示，近7%服用该药物的患者最终住院，其中一人在30天后死亡。相比之下，服用安慰剂的住院患者比例为10%，死亡人数为9人。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已同意购买足够治疗310万人的药物。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约700美元，该疗程要求患者每天两次服用四粒药丸，持续五天。哈佛大学和伦敦国王学院的一项审查估计，每个40粒药丸的疗程费用约为18美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖。这种遗传效应引发了人们的担忧，即该药物可能会导致人类胎儿发生突变，甚至刺激更强的病毒株。但FDA科学家表示，变异风险很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">SeattleTimes</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1,"symbols_score_info":{"MRK":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691641564,"gmtCreate":1640187931332,"gmtModify":1640187931554,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691641564","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohu8.com/m/news/1169752126?lang=zh_CN&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b> is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>在该公司公布好于预期的2022财年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex公布的季度调整后每股收益为91美分，超出了每股80美分的预期。该公司公布季度营收为11.1亿美元，超出预期的10.6亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex表示，预计2022财年收入增长10%至11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said <b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了2022财年第二季度强劲的财务业绩，总收入增长13%，稀释后每股收益增长21%。业绩是由我们客户群中员工的增长以及持续强劲的销售增长和客户保留率推动的，”说<b>马丁·穆奇</b>，Paychex董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex在52周内的交易价格低至85.30美元。周三交易时段创下52周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨5.54%，至133.44美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 23:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Paychex Inc</b> is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>在该公司公布好于预期的2022财年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex公布的季度调整后每股收益为91美分，超出了每股80美分的预期。该公司公布季度营收为11.1亿美元，超出预期的10.6亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex表示，预计2022财年收入增长10%至11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said <b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了2022财年第二季度强劲的财务业绩，总收入增长13%，稀释后每股收益增长21%。业绩是由我们客户群中员工的增长以及持续强劲的销售增长和客户保留率推动的，”说<b>马丁·穆奇</b>，Paychex董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex在52周内的交易价格低至85.30美元。周三交易时段创下52周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨5.54%，至133.44美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1,"symbols_score_info":{"PAYX":0.9}},"isVote":1,"tweetType":1,"viewCount":3496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691029236,"gmtCreate":1640099683076,"gmtModify":1640099683337,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691029236","repostId":"2193154031","repostType":4,"isVote":1,"tweetType":1,"viewCount":2283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693693721,"gmtCreate":1640010977750,"gmtModify":1640010978004,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576377533433583","authorIdStr":"3576377533433583"},"themes":[],"htmlText":"Lime","listText":"Lime","text":"Lime","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693693721","repostId":"1139958745","repostType":4,"repost":{"id":"1139958745","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640010639,"share":"https://www.laohu8.com/m/news/1139958745?lang=zh_CN&edition=full","pubTime":"2021-12-20 22:30","market":"us","language":"en","title":"Dow falls 500 points to start the week as omicron continues to spook markets<blockquote>由于奥密克戎继续令市场恐慌，道琼斯指数本周初下跌500点</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139958745","media":"Tiger Newspress","summary":"Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considerin","content":"<p>Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.</p><p><blockquote>周一，在假期缩短的交易周开始时，股市下跌，投资者考虑海外新的与病毒相关的限制，以及一项重大社会政策法案可能被否决的前景。</blockquote></p><p> The S&P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.</p><p><blockquote>标普500、道指纳斯达克均跌超1%。由于投资者涌入避险资产，美国国债收益率下跌，基准10年期国债收益率保持在1.4%以下。芝加哥期权交易所波动率指数(VIX)飙升逾20%，徘徊在25上方。</blockquote></p><p> U.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend announced a nationwide lockdown of non-essential stores, bars and restaurants until Jan. 14. As of this weekend, the Omicron variant had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.</p><p><blockquote>随着欧洲限制措施的加强，美国原油价格下跌3%，至每桶69美元以下，引发了人们对能源需求的不安。鉴于新变种迅速传播，从德国到爱尔兰等国家最近几天实施了宵禁或旅行限制。荷兰周末宣布在全国范围内封锁非必需品商店、酒吧和餐馆，直至1月14日。截至本周末，约有89个国家报告了奥密克戎变种，病例每1.5至3天翻一番。</blockquote></p><p> Renewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&P 500 and Dow each dropped by nearly 2% for the week.</p><p><blockquote>对奥密克戎变体经济影响的担忧再次加剧，加上上周投资者对收紧货币政策前景的担忧，美联储加快了缩减资产购买的步伐，并暗示明年可能会加息三次。上周，三大指数均出现周线大幅下跌。纳斯达克综合指数下跌3%，标普500指数和道琼斯指数本周均下跌近2%。</blockquote></p><p> Still, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from Pfizer (PFE) and BioNTech (BNTX) from earlier this month about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.</p><p><blockquote>尽管如此，关于当前新冠肺炎疫苗对该变种的影响的其他更新更加乐观。Moderna(MRNA)周一表示，其加强针或第三剂疫苗增加了奥密克戎中和抗体水平。这与辉瑞(PFE)和BioNTech(BNTX)本月早些时候关于其疫苗第三剂中和奥密克戎病毒有效性的结果相呼应。Moderna股价开盘前上涨超过7%。</blockquote></p><p> Investors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.</p><p><blockquote>投资者还消化了参议员乔·曼钦（西弗吉尼亚州民主党人）不会支持乔·拜登总统17.5亿美元的重建更好社会政策法案的意外消息。曼钦周日在福克斯新闻上表示，他已与民主党众议院和参议院领导人以及拜登进行了讨论，但鉴于对通货膨胀、国债和持续大流行的担忧，未能就该法案达成协议。</blockquote></p><p> White House Press Secretary Jen Psakireleased a statement calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.</p><p><blockquote>白宫新闻秘书珍·普萨基（Jen Psaki）发表声明，称曼钦的言论“是他立场的突然且令人费解的逆转”，并表示政府将努力在明年推进立法。</blockquote></p><p> Still, Goldman Sachs this weekend slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.</p><p><blockquote>尽管如此，在曼钦撤回对该法案的支持后，高盛本周末大幅下调了2022年季度GDP预测。以Jan Hatzius为首的经济学家表示，他们预计明年的“财政刺激将比之前预期的更加负面”，因为该法案中没有包括社会和气候相关政策的支出。该公司将2022年第一季度美国GDP预期从3%下调至2%，第二季度从3.5%下调至3%，第三季度从3%下调至2.75%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow falls 500 points to start the week as omicron continues to spook markets<blockquote>由于奥密克戎继续令市场恐慌，道琼斯指数本周初下跌500点</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow falls 500 points to start the week as omicron continues to spook markets<blockquote>由于奥密克戎继续令市场恐慌，道琼斯指数本周初下跌500点</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-20 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.</p><p><blockquote>周一，在假期缩短的交易周开始时，股市下跌，投资者考虑海外新的与病毒相关的限制，以及一项重大社会政策法案可能被否决的前景。</blockquote></p><p> The S&P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.</p><p><blockquote>标普500、道指纳斯达克均跌超1%。由于投资者涌入避险资产，美国国债收益率下跌，基准10年期国债收益率保持在1.4%以下。芝加哥期权交易所波动率指数(VIX)飙升逾20%，徘徊在25上方。</blockquote></p><p> U.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend announced a nationwide lockdown of non-essential stores, bars and restaurants until Jan. 14. As of this weekend, the Omicron variant had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.</p><p><blockquote>随着欧洲限制措施的加强，美国原油价格下跌3%，至每桶69美元以下，引发了人们对能源需求的不安。鉴于新变种迅速传播，从德国到爱尔兰等国家最近几天实施了宵禁或旅行限制。荷兰周末宣布在全国范围内封锁非必需品商店、酒吧和餐馆，直至1月14日。截至本周末，约有89个国家报告了奥密克戎变种，病例每1.5至3天翻一番。</blockquote></p><p> Renewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&P 500 and Dow each dropped by nearly 2% for the week.</p><p><blockquote>对奥密克戎变体经济影响的担忧再次加剧，加上上周投资者对收紧货币政策前景的担忧，美联储加快了缩减资产购买的步伐，并暗示明年可能会加息三次。上周，三大指数均出现周线大幅下跌。纳斯达克综合指数下跌3%，标普500指数和道琼斯指数本周均下跌近2%。</blockquote></p><p> Still, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from Pfizer (PFE) and BioNTech (BNTX) from earlier this month about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.</p><p><blockquote>尽管如此，关于当前新冠肺炎疫苗对该变种的影响的其他更新更加乐观。Moderna(MRNA)周一表示，其加强针或第三剂疫苗增加了奥密克戎中和抗体水平。这与辉瑞(PFE)和BioNTech(BNTX)本月早些时候关于其疫苗第三剂中和奥密克戎病毒有效性的结果相呼应。Moderna股价开盘前上涨超过7%。</blockquote></p><p> Investors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.</p><p><blockquote>投资者还消化了参议员乔·曼钦（西弗吉尼亚州民主党人）不会支持乔·拜登总统17.5亿美元的重建更好社会政策法案的意外消息。曼钦周日在福克斯新闻上表示，他已与民主党众议院和参议院领导人以及拜登进行了讨论，但鉴于对通货膨胀、国债和持续大流行的担忧，未能就该法案达成协议。</blockquote></p><p> White House Press Secretary Jen Psakireleased a statement calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.</p><p><blockquote>白宫新闻秘书珍·普萨基（Jen Psaki）发表声明，称曼钦的言论“是他立场的突然且令人费解的逆转”，并表示政府将努力在明年推进立法。</blockquote></p><p> Still, Goldman Sachs this weekend slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.</p><p><blockquote>尽管如此，在曼钦撤回对该法案的支持后，高盛本周末大幅下调了2022年季度GDP预测。以Jan Hatzius为首的经济学家表示，他们预计明年的“财政刺激将比之前预期的更加负面”，因为该法案中没有包括社会和气候相关政策的支出。该公司将2022年第一季度美国GDP预期从3%下调至2%，第二季度从3.5%下调至3%，第三季度从3%下调至2.75%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139958745","content_text":"Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.\nThe S&P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.\nU.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend announced a nationwide lockdown of non-essential stores, bars and restaurants until Jan. 14. As of this weekend, the Omicron variant had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.\nRenewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&P 500 and Dow each dropped by nearly 2% for the week.\nStill, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from Pfizer (PFE) and BioNTech (BNTX) from earlier this month about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.\nInvestors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.\nWhite House Press Secretary Jen Psakireleased a statement calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.\nStill, Goldman Sachs this weekend slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}